Skyrizi® ,
Risankizumab-rzaa
Disease
Crohn's disease
,
Drug Class
Biologics/Biosimilars
Delivery Method
IV
or
Injection
or
Brand name:
Skyrizi®
,
Drug name:
Risankizumab-rzaa
Drug type
Interleukin-23 Antagonist
Recommendations for pregnancy
Insufficient trial data. Monoclonal antibodies may be transported across the placenta
Most common side effects
It may increase risk of infections including upper respiratory or urinary tract infections. Other side effects may include injection site reactions, abdominal pain, headache, and joint pains. Liver injury has been reported (liver enzymes and bilirubin levels should be monitored).
Other
Patients should be evaluated for tuberculosis (TB) prior to starting this medication, and should not be given Skyrizi® if there is active TB. If there is a hypersensitivity reaction or anaphylaxis occurs, discontinue medication and initiate appropriate therapy immediately. Avoid use of live vaccines
Learn more about
Biologics/Biosimilars